Masimo (NASDAQ:MASI) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Masimo (NASDAQ:MASI) released its earnings results on Tuesday. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.09, Briefing.com reports. The company had revenue of $496.30 million for the quarter, compared to analyst estimates of $493.92 million. Masimo had a return on equity of 13.26% and a net margin of 4.01%. Masimo’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.62 EPS.

Masimo Trading Down 0.8 %

Masimo stock traded down $1.07 during trading hours on Friday, hitting $126.87. The stock had a trading volume of 651,209 shares, compared to its average volume of 677,744. The company has a quick ratio of 1.31, a current ratio of 2.31 and a debt-to-equity ratio of 0.62. The stock has a market cap of $6.75 billion, a price-to-earnings ratio of 87.76 and a beta of 0.97. Masimo has a one year low of $75.22 and a one year high of $153.93. The business’s 50 day simple moving average is $118.82 and its 200-day simple moving average is $127.81.

Analysts Set New Price Targets

MASI has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday. Piper Sandler raised their price objective on Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Stifel Nicolaus raised Masimo from a “hold” rating to a “buy” rating and raised their price objective for the company from $148.00 to $170.00 in a research note on Monday, April 15th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $144.29.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.